Legend Biotech Surges 18% After Eli Lilly Strikes $7 Billion Cancer Therapy Deal
NEW YORK, April 21 —
Eli Lilly committed roughly $7 billion to Legend Biotech's CARVYKTI franchise, sending LEGN up as much as 18% for its best day in three years.
- LEGN gained 9-18% on the session after multiple outlets confirmed the deal; shares traded near $24.93
- HC Wainwright reiterated Buy with a $50 price target, implying roughly 100% upside from recent levels
- Next catalyst: definitive deal terms plus CARVYKTI sales data in Legend's upcoming quarterly earnings report
What Actually Happened
Lilly is buying its way into CAR-T therapy, the class of cancer treatments that reprogram a patient's own immune cells to attack tumors. CARVYKTI, Legend's lead asset, already generates $1.0bn in trailing twelve-month revenue. That is real commercial traction, not a Phase 2 dream. The deal positions Lilly to compete directly with the two incumbents in CAR-T: Johnson & Johnson (Legend's existing partner on CARVYKTI) and Gilead, which sells the rival therapy Yescarta.
Raymond James reiterated its positive stance on the back of strong clinical trial data, while HC Wainwright's $50 target suggests the Street thinks the current price badly undervalues the asset. At 21.7x forward earnings, LEGN is not priced like a billion-dollar-revenue biotech with a pharma giant writing checks.
The Catch
The deal terms are still described as approximate. "Roughly $7 billion" and "related strategic transaction" are doing a lot of work in that sentence. Until definitive terms land, the actual per-share value to LEGN holders is unclear. CAR-T therapies also face a structural problem: manufacturing is brutally complex, requiring individualized production for each patient. Legend has been expanding US manufacturing capacity, but scaling a personalized therapy is not the same as scaling a pill. Gilead learned this the hard way with Yescarta's slower-than-expected ramp.
There is also the J&J question. Johnson & Johnson has an existing partnership with Legend on CARVYKTI. How Lilly's deal interacts with that relationship, and whether J&J has any rights that complicate the transaction, matters enormously for the final number shareholders actually receive.
Bottom Line
This deal is a validation event. When Eli Lilly, one of the world's largest pharma companies, pays $7bn to enter your market through your product, the "is this real?" debate is over. The question now is whether $7bn is enough. HC Wainwright's $50 target is double the current price, and competing bids are not out of the question in a hot oncology M&A market. The number to watch: definitive deal terms and any signal from J&J about its own stake in the CARVYKTI relationship.
Legend Biotech does not yet have a Basis Report. Generate a full LEGN equity report here to dig into the financials behind this deal.
Basis Report does not hold positions in securities discussed. This is not investment advice.